Table 3.
Relation Between Intensity (Protein Expression) and Clinicopathological Parameters of EOC
| Pathological Data | STAGE |
GRADE |
Neoadjuvant Chemo |
|||
|---|---|---|---|---|---|---|
| I+II | III+IV | Low | High | No | Yes | |
| IGF1R | ||||||
| Low | 6 (60%) | 6 (23.1%) | 4 (57.1%) | 8 (27.6%) | 10 (52.6%) | 2 (11.8%) |
| High | 4 (40%) | 20 (76.9%)* | 3 (42.9%) | 21 (72.4%) | 9 (47.4%) | 15 (88.2%)* |
| p53 | ||||||
| Low | 1 (10%) | 6 (23.1%) | 2 (28.6%) | 5 (17.2%) | 2 (10.5%) | 5 (29.4%) |
| High | 9 (90%) | 20 (76.9%) | 5 (71.4%) | 24 (82.8%) | 17 (85.9%) | 12 (70.6%) |
| Ki67 | ||||||
| Low | 6 (60%) | 12 (46.2%) | 6 (85.7%) | 12 (41.4%) | 7 (36.8%) | 11 (64.7%) |
| High | 4 (40%) | 14 (53.8%) | 1 (14.3%) | 17 (58.6%) | 12 (63.2%) | 6 (35.3%) |
| BRCA1 | ||||||
| Low | 5 (50%) | 17 (65.4%) | 5 (71.4%) | 17 (58.6%) | 11 (57.9%) | 11 (64.7%) |
| High | 5 (50%) | 9 (34.6%) | 2 (28.6%) | 12 (41.4%) | 8 (42.1%) | 6 (53.3%) |
| CD1c | ||||||
| Low | 8 (80%) | 12 (46.2%) | 5 (71.4%) | 15 (51.7%) | 12 (63.2%) | 8 (47.1%) |
| High | 2 (20%) | 14 (53.8%) | 2 (28.6%) | 14 (48.3%) | 7 (36.8) | 9 (52.9%) |
| CD141 | ||||||
| Low | 6 (60%) | 17 (65.4%) | 5 (71.4%) | 18 (62.1%) | 12 (63.2%) | 11 (64.7%) |
| High | 4 (40%) | 9 (34.6%) | 2 (28.6%) | 11 (37.9%) | 7 (36.8%) | 6 (35.3%) |